Skip to main content
Offering could pull in $13.7M for Interpace Diagnostics

A public offering of 12.5 million shares of common stock and warrants to buy up to 12.5 million additional shares has been priced by Interpace Diagnostics in hopes of obtaining $13.7 million in gross proceeds. The company intends to use the $12.7 million net proceeds as working capital, as well as for general corporate functions, payment of legacy contract sales organization obligations and trade payables.

Full Story: